Read this company snapshot
Daily valuation snapshot
Spruce Biosciences, Inc. Common Stock: source evidence dated 2026-10-09.
- Daily close (USD)
- $44.05
- Market capitalization (USD)
- $126,600,272.65
- Price / earnings (TTM)
- Not reported
- Price / book
- 1.51
The source values and product destination above identify the example to inspect.
What business is this, and what does its dated valuation mean?
Check the market day first. P/E uses trailing earnings; book value and market capitalization answer different questions.
Daily valuation dataset and column definitionsOpen the company research view or ask Aurora to reconcile reporting periods, earnings, debt and the figures behind the valuation.
Research SPRB in the app
Open the company research view or ask Aurora to reconcile reporting periods, earnings, debt and the figures behind the valuation.
Research SPRB in the appKeep reporting dates and units beside the answer, and inspect its original citations.
Company overview
Spruce Biosciences, Inc. is a biopharmaceutical company focused on developing and commercializing novel therapies for neurological disorders. The company develops TA-ERT, a fusion protein comprised of recombinant human alpha-N-acetylglucosaminidase, which is an enzyme replacement therapy for patients with Sanfilippo Syndrome Type B. It also develops Tildacerfont for treating a highly debilitating mental disorder characterized by depressed mood with cognitive-affective and somatic changes, including anhedonia, weight alterations, and altered sleeping patterns. In addition, the company develops SPR202 for the treatment of Congenital Adrenal Hyperplasia (CAH), a chronic and potentially life-threatening rare disease with no cure, and SPR204, a monoclonal antibody antagonist for Post-Bariatric Hypoglycemia. The company has a license agreement with Eli Lilly and Company to research, develop, and commercialize various pharmaceutical compounds. It also has a collaboration and license agreement with Kaken Pharmaceutical Co. Ltd. to develop, manufacture, and commercialize Tildacerfont for the treatment of CAH in Japan. Spruce Biosciences, Inc. was incorporated in 2014 and is headquartered in South San Francisco, California.
Daily valuation snapshot
See the complete daily valuation snapshot
These values come from the daily market snapshot dated 2026-10-09. TTM means trailing twelve months. Use the market date when comparing SPRB with another company.
Scroll sideways to compare all columns. Select a heading to sort.
| Daily close (USD) | $44.05 |
| Market capitalization (USD) | $126,600,272.65 |
| Price / earnings (TTM) | Not reported |
| Price / book | 1.51 |
No matching rows. Clear the filter to see all records.
Read SPRB's valuation metrics
Company size
Spruce Biosciences, Inc. Common Stock's recorded market capitalization is $126,600,272.65. It measures the market value of the company's equity, rather than its revenue or cash balance.
Price relative to earnings
P/E compares share price with trailing annual earnings per share. For a company with losses, inspect the earnings figures directly rather than treating a negative multiple as a cheap valuation.
Price relative to book equity
SPRB's recorded price-to-book ratio is 1.51. That compares its market equity value with recorded book equity. Examine its business and balance sheet to understand why those values differ.
Research Spruce Biosciences, Inc. Common Stock with Aurora
Use the snapshot above to ask a specific question about SPRB. Ask for the report period and the figures behind the explanation, then compare the answer with the company's business description.
Continue the research
Follow SPRB's ownership disclosures to see who filed a transaction or position and when it became public. To turn a research idea into a strategy, define an entry rule and test its dated observations.